Article in Nature cardiovascular research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Junchen LiuDepartment of Integrative Biology and Pharmacology, McGovern Medical School, University of Texas Health Science Center, Houston, TX, USA.
Guangyu WangDepartment of Cardiovascular Sciences, Houston Methodist Research Institute, Houston, TX, USA.
John P CookeDepartment of Cardiovascular Sciences, Houston Methodist Research Institute, Houston, TX, USA.
Li LaiDepartment of Cardiovascular Sciences, Houston Methodist Research Institute, Houston, TX, USA. llai@houstonmethodist.org.ORCID http://orcid.org/0000-0002-5731-2705
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DIANE BODURKA · 1985 to 2026
$290.8M
Reversal of Heart Failure: Role of Vascular RecoveryR01HL148338 · NHLBI · METHODIST HOSPITAL RESEARCH INSTITUTE · PI CHEN, KAIFU, COOKE, JOHN P · 2020 to 2023
$2.8M
Metabolism and Epigenetic Regulation are Couples in Transdifferentiation and Vascular RegenerationR01HL169204 · NHLBI · METHODIST HOSPITAL RESEARCH INSTITUTE · PI Li Lai · 2024 to 2026
$1.8M
Role of S-nitrosylation in TransdifferentiationR01HL133254 · NHLBI · METHODIST HOSPITAL RESEARCH INSTITUTE · PI CHEN, KAIFU, COOKE, JOHN P · 2018 to 2021
$1.6M
Landscapes for Cell State Transition Leveraging by Single-Cell Multi-OmicsR35GM150460 · NIGMS · METHODIST HOSPITAL RESEARCH INSTITUTE · PI Guangyu Wang · 2023 to 2026
$1.6M
Regulation of KRAS plasma membrane targeting by defined glycosphingolipids.R01GM151280 · NIGMS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI Alemayehu A. Gorfe, JOHN F HANCOCK · 2023 to 2026
$1.6M
Orbitrap Elite High-Resolution Mass Spectrometer for Proteomics and MetabolomicsS10OD012304 · OD · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI HAWKE, DAVID H · 2013 to 2013
$877k
Metabolism and Epigenetic Regulation are Couples in Transdifferentiation and Vascular RegenerationR56HL169204 · NHLBI · METHODIST HOSPITAL RESEARCH INSTITUTE · PI LAI, LI · 2023 to 2023
$404k
Vascular Biology 2023 - Annual Meeting of the North American Vascular Biology OrganizationR13HL167547 · NHLBI · NORTH AMERICAN VASCULAR BIOLOGY ORG · PI ZHENG, YING · 2023 to 2023
$40k
American Heart Association (American Heart Association, Inc.) 25POST1378365Cancer Prevention and Research Institute of Texas (Cancer Prevention Research Institute of Texas) RP150611Cancer Prevention and Research Institute of Texas (Cancer Prevention Research Institute of Texas) RP250213NCI NIH HHS P30 CA016672NHLBI NIH HHS R01 HL133254NHLBI NIH HHS R01 HL148338NHLBI NIH HHS R01 HL169204NHLBI NIH HHS R13 HL167547NHLBI NIH HHS R56 HL169204NIGMS NIH HHS R01 GM151280NIGMS NIH HHS R35 GM150460NIH HHS S10 OD012304U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI) F30 HL167547U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI) HL133254U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI) HL148338U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI) HL1577990U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI) HL169204-01A1U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (NIGMS) 1R35GM150460U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (NIGMS) GM151280
6 · The paper itself
Abstract
The restoration of the microvasculature is essential to cardiovascular regeneration. Our previous work demonstrated that angiogenic transdifferentiation of fibroblasts into endothelial cells facilitates vascular recovery following limb ischemia and is accompanied by a metabolic shift toward glycolysis. However, a comprehensive characterization of the metabolic alterations that contribute to the transdifferentiation process is still lacking. Here we identify a marked upregulation of uridine diphosphate N-acetylglucosamine (UDP-GlcNAc), the substrate for O-GlcNAcylation, during transdifferentiation. Enhancing this pathway promotes, whereas inhibiting it impairs, the efficiency of transdifferentiation. Mechanistically, we demonstrate that O-GlcNAcylation facilitates chromatin remodeling through modification of HIRA, a histone chaperone responsible for de novo deposition of the noncanonical histone variant H3.3, a process intimately linked to transcriptional activation. These findings are further supported by in vivo lineage tracing and conditional knockout mouse models. Collectively, our study demonstrates that O-GlcNAcylation enhances angiogenic transdifferentiation through a metabolic-and-epigenetic-coupled mechanism, thereby strengthening vascular recovery.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
O-GlcNAcylation promotes angiogenic transdifferentiation to reverse vascular ischemia. · full record | OpenQuestion